Saturday, March 28, 2015
1:00 p.m.–5:00 p.m.
Jack Stein, PhD, National Institute on Drug Abuse (NIDA), Bethesda, MD
Charles P. O’Brien, MD, University of Pennsylvania, Philadelphia, PA
Maria A. Sullivan, MD, Columbia University, New York, NY
William Marrone, DO, Synergy Medical Education Alliance, Saginaw, MI
Injectable naltrexone is a relatively new medication to prevent opioid misuse relapse. Naltrexone is a long-acting opioid antagonist with a high affinity for the mu-opioid receptor. Maintenance therapy with naltrexone has been strongly associated with extremely motivated patients or with use in controlled settings. Moreover, additional medications and formulations of currently approved medications are under development for the treatment of opioid dependence.
With the rise in prescription opioid abuse and the transition of these patients to heroin, the co-prescribing of naloxone is increasing in popularity. This session highlights medications for treating opioid dependence and overdose and non-opioid pharmacotherapy options that can be used in Opioid Treatment Programs.
Sponsored by the National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental Health Services Administration (SAMHSA)
Please go to http://www.aatod.org/national-conference/2015-aatod-conference-atlanta/continuing-education-credit/ for more information on continuing education credits for each section of the website.